AstraZeneca PLC

AZN: XLON (GBR)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|fD?<LOCK|$^LOCK|q$<Br<&R

AstraZeneca Earnings: Amid Second-Quarter Results, Full-Year Guidance Unchanged

AstraZeneca reported 11% year-on-year revenue growth, excluding a 1% currency headwind, and core operating profit growth of 14%. Management reiterated its full-year guidance of high single-digit revenue growth and low-double-digit core earnings per share growth.

Sponsor Center